Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 December 2003, Vol. 102, No. 13, pp. 4261-4269.
Prepublished online as a Blood First Edition Paper on August 7, 2003; DOI 10.1182/blood-2003-05-1675.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2003-05-1675v1
102/13/4261    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Belhadj, K.
Right arrow Articles by Gaulard, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Belhadj, K.
Right arrow Articles by Gaulard, P.
Related Collections
Right arrow Neoplasia
Right arrow Clinical Trials and Observations
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS

Hepatosplenic {gamma}{delta} T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

Karim Belhadj, Félix Reyes, Jean-Pierre Farcet, Hervé Tilly, Christian Bastard, Régis Angonin, Eric Deconinck, Frédéric Charlotte, Véronique Leblond, Eric Labouyrie, Pierre Lederlin, Jean-François Emile, Béatrice Delmas-Marsalet, Bertrand Arnulf, Elie-Serge Zafrani, and Philippe Gaulard

From the Service d'Hématologie Clinique, the Service d'Immunologie Biologique and the Département de Pathologie and EA2348, Centre Hospitalier Universitaire (CHU) Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France; Service d'Hématologie Clinique and Laboratoire de Cytogénétique, Centre Henri Becquerel, Rouen, France; Service d'Anatomie Pathologique and Service d'Hématologie Clinique, CHU de Besançon, Besançon, France; Service d'Anatomie Pathologique and Service d'Hématologie Clinique, CHU Pitié-Salpêtrière, Paris, France; Service d'Anatomie Pathologique and Service d'Hématologie Clinique, CHU de Nancy, Nancy, France; Service d'Anatomie Pathologie and Service d'Hématologie Clinique, CHU Paul Brousse, Villejuif, France; and Service d'Hématologie Clinique, CHU Necker, Paris, France.

We report on the characteristics of 21 patients with hepatosplenic {gamma}{delta} T-cell lymphoma (HS{gamma}{delta}TCL), an entity recognized since 1994 in the Revised European American Lymphoma (REAL) classification. Median age was 34 years. Patients had splenomegaly (n = 21), hepatomegaly (n = 15), and thrombocytopenia (n = 20). Histopathologic findings were homogeneous and showed the presence of medium-sized lymphoma cells within the sinusoids of splenic red pulp, liver, and bone marrow. Marrow involvement was usually mild but could be demonstrated by phenotyping in all patients. Cells were CD3+CD5-, expressed the {gamma}{delta} T-cell receptor, and had a nonactivated cytotoxic cell phenotype (TIA-1+, granzyme B-). Most patients were CD4-/CD8- (16 of 18); CD56+ (15 of 18), expressed the V{delta}1epitope (Vd1+/Vd2-/Vd3-) (9 of 12); and were negative for Epstein-Barr virus (EBV) (18 of 20). Isochromosome arm 7q was documented in 9 of 13 patients. Eight patients had previously undergone kidney transplantation or had a history of systemic lupus, Hodgkin disease, or malaria. Prognosis was poor; median survival time was 16 months, and all but 2 patients ultimately died despite consolidative or salvage high-dose therapy. In conclusion, HS{gamma}{delta}TCL is a disease with distinctive clinical, histopathologic, and phenotypic characteristics. Bone marrow biopsy with combined phenotyping is sufficient for diagnosis, and splenectomy is therefore unwarranted. Current treatment modalities appear to be ineffective in most patients. (Blood. 2003;102:4261-4269)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
NEJMHome page
J. S. Abramson, M. Chatterji, and A. Rahemtullah
Case 39-2008 -- A 51-Year-Old Woman with Splenomegaly and Anemia
N. Engl. J. Med., December 18, 2008; 359(25): 2707 - 2718.
[Full Text] [PDF]


Home page
JCOHome page
S. Le Gouill, N. Milpied, A. Buzyn, R. Peffault De Latour, J.-P. Vernant, M. Mohty, M.-P. Moles, K. Bouabdallah, C.-E. Bulabois, J. Dupuis, et al.
Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire
J. Clin. Oncol., May 10, 2008; 26(14): 2264 - 2271.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. S. Abramson, C. N. Kotton, N. Elias, D. V. Sahani, and R. P. Hasserjian
Case 8-2008 -- A 33-Year-Old Man with Fever, Abdominal Pain, and Pancytopenia after Renal Transplantation
N. Engl. J. Med., March 13, 2008; 358(11): 1176 - 1187.
[Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
K N Naresh, I Lampert, R Hasserjian, D Lykidis, K Elderfield, D Horncastle, N Smith, W Murray-Brown, and G W Stamp
Optimal processing of bone marrow trephine biopsy: the Hammersmith Protocol.
J. Clin. Pathol., September 1, 2006; 59(9): 903 - 911.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
K. Chakravarty, A. Kuttikat, I. Saeed, and R. Thompson
Rheumatoid arthritis, Pyrexia of Unknown Origin (PUO) and pancytopenia
Rheumatology, April 1, 2006; 45(4): 386 - 391.
[Full Text] [PDF]


Home page
BloodHome page
M. A. Rizvi, A. M. Evens, M. S. Tallman, B. P. Nelson, and S. T. Rosen
T-cell non-Hodgkin lymphoma
Blood, February 15, 2006; 107(4): 1255 - 1264.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
E. S. Jaffe
Pathobiology of Peripheral T-cell Lymphomas
Hematology, January 1, 2006; 2006(1): 317 - 322.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
J. P. Greer
Therapy of Peripheral T/NK Neoplasms
Hematology, January 1, 2006; 2006(1): 331 - 337.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
K. J. Savage
Aggressive Peripheral T-Cell Lymphomas (Specified and Unspecified Types)
Hematology, January 1, 2005; 2005(1): 267 - 277.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020